2-[(2,4-dichloro-6-methylphenyl)amino]-5-ethylbenzeneacetic acid | 346670-74-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[(2,4-dichloro-6-methylphenyl)amino]-5-ethylbenzeneacetic acid
• 英文别名: [2-(2,4-dichloro-6-methyl-phenylamino)-5-ethyl-phenyl]-acetic acid；5-ethyl-2-(2',4'-dichloro-6'-methylanilino)phenylacetic acid；COX-189；2-[2-(2,4-dichloro-6-methylanilino)-5-ethylphenyl]acetic acid
• CAS: 346670-74-4
• 化学式: C₁₇H₁₇Cl₂NO₂
• 分子量: 338.233
• InChiKey: OKGJGFZQNSWNSS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES INTRANASALES D'INHIBITEURS DE CGRP
  申请人：BIOHAVEN PHARM HOLDING CO LTD

  公开号：WO2021127070A1

  公开（公告）日：2021-06-24

  Provided is pharmaceutical composition for intranasal delivery, wherein the pharmaceutical composition includes a therapeutically active ingredient including a CGRP inhibitor. Also provided is a method for delivering a CGRP inhibitor to a subject, wherein the method includes intranasally administering to the subject a composition including a therapeutically active component including a CGRP inhibitor.

  提供了一种用于鼻内给药的药物组合物，其中该药物组合物包括一种治疗有效成分，该治疗有效成分包括CGRP抑制剂。还提供了一种将CGRP抑制剂递送给主体的方法，该方法包括将包括治疗有效成分的药物组合物鼻内给药给主体，该治疗有效成分包括CGRP抑制剂。
• Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders
  申请人：Pharmacia Corporation

  公开号：US20040220187A1

  公开（公告）日：2004-11-04

  The present invention provides compositions and methods for the treatment of pain, inflammation or inflammation-mediated disorders in a subject. More particularly, the invention provides a combination therapy for the treatment of pain, inflammation or inflammation mediated disorders comprising the administration to a subject of a sodium ion channel blocker in combination with a cyclooxygenase-2 selective inhibitor.

  本发明提供了用于治疗疼痛、炎症或炎症介导性疾病的组合物和方法。更具体地，本发明提供了一种联合疗法，用于治疗疼痛、炎症或炎症介导性疾病，包括向受试者施用钠离子通道阻滞剂与环氧合酶-2选择性抑制剂的组合。
• Process for phenylacetic acid derivatives
  申请人：Acemoglu Murat

  公开号：US20080249318A1

  公开（公告）日：2008-10-09

  A process for the production of a compound of Formula I, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug ester thereof, comprising cleaving a lactam of formula II wherein the symbols are as defined, with a base; and precursors therefor and processes for the preparation of the precursors. The compounds of Formula I are pharmaceutically active compounds which are selective inhibitors of Cyclooxygenase II.

  生产Formula I化合物或其药用可接受盐或其药用可接受的前药酯的过程，包括用碱裂解Formula II的内酰胺，其中符号的定义如上；以及前体和前体的制备过程。Formula I化合物是具有药理活性的化合物，是环氧合酶II的选择性抑制剂。
• Method for the treatment and prevention of cachexia
  申请人：Washington University

  公开号：US20030087942A1

  公开（公告）日：2003-05-08

  Cachexia, including anorexia and other forms of weight loss, is a frequent complication of acute and chronic infections, and result from induction of cytokines, prostaglandins, and other inflammatory mediators that are critical for pathogen elimination. The present invention includes methods for the treatment or prevention of cachexic conditions while maintaining the production of factors essential for infection control through the administration of an effective amount of a cyclooxygenase-2 selective inhibiting compound.

  消瘦症，包括厌食和其他形式的体重减轻，是急性和慢性感染的常见并发症，由细胞因子、前列腺素和其他炎症介质的诱导引起，这些介质对病原体清除至关重要。本发明包括通过给予有效量的环氧合酶-2选择性抑制化合物来治疗或预防消瘦症状，同时保持对感染控制至关重要的因子的产生的方法。
• [EN] PROCESS FOR PHENYLACETIC ACID DERIVATIVES<br/>[FR] PROCEDES DE PRODUCTION DE PRODUITS DERIVES D'ACIDES PHENYLACETIQUES
  申请人：NOVARTIS AG

  公开号：WO2001023346A2

  公开（公告）日：2001-04-05

  A process for the production of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug ester thereof, comprising cleaving a lactam of formula (II) wherein the symbols are as defined, with a base; and precursors therefor and processes for the preparation of the precursors. The compounds of formula (I) are pharmaceutically active compounds which are selective inhibitors of Cyclooxygenase (II).

  一种生产式(I)化合物、其药学上可接受的盐或药学上可接受的前药酯的方法，包括用碱水解式(II)内的内酰胺，其中符号如定义的；以及其前体和制备前体的方法。式(I)化合物是具有药学活性的化合物，是环氧合酶(II)的选择性抑制剂。